First-line treatment with surufatinib, camrelizumab, nab-paclitaxel, and S-1 in locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC): A phase Ib/II randomized study.

Authors: Guang-Hai Dai, Ru Jia, Hai-Yan Si, Meng-Jiao Fan, Nan Zhang, Quanli Han, Zhi-Kuan Wang, Guo-Chao Deng, Fang-Fang Liu, Lu Han, Miaomiao Gou, Zhaoli Tan, Xia Zhang, Yue Shi, Yao-Yue Zhang, Yu-Shan Jia

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.4161

Source: Full article

---

Abstract

4161